Published in Cancer Weekly, January 31st, 2006
The merger is expected to create a transatlantic, Nasdaq-listed company with a highly differentiated drug-development pipeline focused on oncology, autoimmune, and inflammatory diseases, and a strong, proprietary technology base for the development of antibody-based product candidates.
"We believe that the proposed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.